Huateng Pharma

Hunan Huateng Pharmaceutical Co., Ltd, a global leader in PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services, cordially invites you to visit our booth at CPhI Japan 2024, held from April 17th to 19th at Tokyo Big...

Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain.

Huateng Pharma, a Contract Development and Manufacturing Organization (CDMO) specializing in APIs and intermediates, is proud to announce its featured product line catering specifically to the veterinary industry.

Huateng Pharma, a leading supplier of high-quality ingredients for the pharmaceutical and cosmetic industries, is proud to announce its range of novel ingredients designed for both commodities and cosmetics.

Huateng Pharma, a leading innovator in pharmaceutical intermediates, is proud to announce the introduction of its latest product line - Gastrointestinal API Intermediates, featuring the groundbreaking compounds Fexuprazan and Vonoprazan Intermediates.

Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral drug for the treatment of refractory hypertension in the 1970s.

Diabetes is a serious chronic disease characterized by elevated blood sugar concentrations associated with the effects of abnormal beta cell biology on insulin action.

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women.

SGLT-2 inhibitor is a new type of oral hypoglycemic drug that has received great attention in recent years.

In recent years, targeted protein degradation (TPD) technology has developed rapidly, especially proteolysis targeting chimera (PROTAC), which is the most representative technology of TPD strategy.